Tag

Baricitinib

3 articles

After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and more

Bajaj Healthcare has applied for a compulsory license against Eli Lilly for Baricitinib, citing affordability concerns. The post also covers the EPO's decision on double patenting, updates from…

Gaurav Mishra · 28 Jun 2021

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates…

Gaurav Mishra · 24 May 2021

Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more

Natco seeks a compulsory license for Baricitinib, while the USA backs a temporary COVID-19 vaccine patent waiver. The EU critiques the US approach, and Ericsson and Samsung resolve…

Gaurav Mishra · 10 May 2021

IP Rights

News & Analysis

Practice & Business

Tech, Media & Society

Specialised

Baricitinib

After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and more

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more